Compile Data Set for Download or QSAR
Report error Found 14 Enz. Inhib. hit(s) with all data for entry = 8598
TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406350(US10336731, Compound 2, (+))
Affinity DataIC50: 380nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406351(US10336731, Compound 2, racemic)
Affinity DataIC50: 398nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406346(US10336731, Compound 1, (+))
Affinity DataIC50: 398nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406352(US10336731, Compound 3)
Affinity DataIC50: 437nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406353(US10336731, Compound 4)
Affinity DataIC50: 447nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406355(US10336731, Compound 6)
Affinity DataIC50: 1.10E+3nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406348(US10336731, Compound 1, racemic)
Affinity DataIC50: 1.26E+3nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406356(US10336731, Compound 7, racemic)
Affinity DataIC50: 1.35E+3nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406345(US10336731, Compound REF 3)
Affinity DataIC50: 1.45E+3nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406347(US10336731, Compound 1, (-))
Affinity DataIC50: 1.70E+3nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406349(US10336731, Compound 2, (-))
Affinity DataIC50: 2.88E+3nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406343(US10336731, Compound REF 1)
Affinity DataIC50: 3.80E+3nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406344(US10336731, Compound REF 2)
Affinity DataIC50: 6.76E+3nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM406354(US10336731, Compound 5)
Affinity DataIC50: 1.45E+4nMAssay Description:0.17 μM of human IDO protein was pre-incubated for 120 min at RT with test compounds in the presence of 50 mM KPO4, pH 7.0, 0.5 mM EDTA, 0.5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent